242 related articles for article (PubMed ID: 23711057)
1. [PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview].
Adam Z; Szturz P; Křen L; Krejčí M; Pour L; Svoboda T; Hanke I; Penka I; Koukalová R; Rehák Z; Cervinková I; Storková T; Král Z; Mayer J
Vnitr Lek; 2013 Apr; 59(4):301-12. PubMed ID: 23711057
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Adam Z; Szturz P; Krejčí M; Koukalová R; Michalková E; Řehák Z; Pourová E; Pour L; Volfová P; Sandecká V; Čermáková Z; Křen L; Sokol F; Hanke I; Penka I; Petrášová H; Ševčíková S; Král Z; Mayer J
Vnitr Lek; 2016 Apr; 62(4):287-98. PubMed ID: 27250606
[TBL] [Abstract][Full Text] [Related]
3. [Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations - case report and literature review].
Szturz P; Adam Z; Moulis M; Smardová L; Klincová M; Slaisová R; Koukalová R; Rehák Z; Volfová P; Chovancová J; Stehlíková O; Mayer J
Vnitr Lek; 2012 Sep; 58(9):679-90. PubMed ID: 23094815
[TBL] [Abstract][Full Text] [Related]
4. [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Adam Z; Pour L; Krejčí M; Zahradová L; Szturz P; Koukalová R; Rehák Z; Nebeský T; Hájek R; Král Z; Mayer J
Vnitr Lek; 2012 Nov; 58(11):856-66. PubMed ID: 23256832
[TBL] [Abstract][Full Text] [Related]
5. [PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review].
Adam Z; Szturz P; Koukalová R; Řehák Z; Pour L; Krejčí M; Šmardová L; Eid M; Volfová P; Čermáková Z; Křen L; Sokol F; Hanke I; Michalková E; Král Z; Mayer J
Vnitr Lek; 2015 Mar; 61(3):251-9. PubMed ID: 25873122
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
[TBL] [Abstract][Full Text] [Related]
7. [Castleman disease: retrospective single-center study of therapeutic results in 10 patients].
Szturz P; Adam Z; Rehák Z; Koukalová R; Sprláková-Puková A; Michalka J; Smardová L; Volfová P; Lengerová M; Mayer J
Klin Onkol; 2013; 26(2):124-34. PubMed ID: 23718671
[TBL] [Abstract][Full Text] [Related]
8. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for POEMS syndrome.
Kim SY; Lee SA; Ryoo HM; Lee KH; Hyun MS; Bae SH
Ann Hematol; 2006 Aug; 85(8):545-6. PubMed ID: 16718498
[No Abstract] [Full Text] [Related]
10. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Lee FC; Merchant SH
Am J Hematol; 2003 May; 73(1):48-53. PubMed ID: 12701121
[TBL] [Abstract][Full Text] [Related]
11. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
13. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
[TBL] [Abstract][Full Text] [Related]
14. [Castlemans disease].
Majerčáková D
Vnitr Lek; 2012 Mar; 58(3):216-20. PubMed ID: 22486288
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
17. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide.
Starkey CR; Joste NE; Lee FC
Am J Hematol; 2006 Apr; 81(4):303-4. PubMed ID: 16550518
[No Abstract] [Full Text] [Related]
18. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma.
Král Z; Adam Z; Folber F; Moulis M; Tomíška M; Říhová L; Štork M; Buliková A; Pour L; Krejčí M; Sandecká V; Koukalová R; Řehák Z; Čermáková Z
Vnitr Lek; 2019; 65(1):37-44. PubMed ID: 30823836
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
